Print Page | Close Window

News Release

Printer Friendly Version View printer-friendly version
<< Back
Valeant Pharmaceuticals to Announce 2010 Third Quarter Results on November 4, 2010

ALISO VIEJO, Calif., Oct 25, 2010 /PRNewswire via COMTEX/ --

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, November 4, 2010 at 8:00 a.m. EDT (5:00 a.m. PDT) to discuss results for the 2010 third quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code18324045. International callers should dial (973) 200-3961, confirmation code 18324045. A replay will be available approximately two hours following the conclusion of the conference call to Thursday, November 11, 2010, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 18324045.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:


Contact for Valeant

Laurie W. Little

949-461-6002

laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101025/LA87217LOGO)

SOURCE Valeant Pharmaceuticals International, Inc.